CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis

Background The lack of positive costimulatory molecules represents one of the mechanisms by which tumor cells evade immune surveillance. Promoter hypermethylation plays a major role in cancer development through transcriptional silencing of critical genes. The aim of this study was to examine the expression of the costimulatory molecule CD80 in relationship with genomic methylation in non-inflammatory colon carcinogenesis. Methods Colonic mucosal samples were collected from healthy subjects (n = 30) and from dysplastic adenoma (n = 14), and colon adenocarcinoma (n = 10). DNA methyltransferases-1, −3a, −3b and CD80 mRNA expression were quantified by real time qRT-PCR. The methylation status of CDH13, APC, MLH1, MGMT1 and RUNX3 gene promoters was assessed by methylation-specific PCR. CD80 expression was assessed in HT29, HCT-15 and LoVo cell lines after treatment with the DNA-methyltransferase inhibitor 5-Aza-2′-deoxycytidine. Results CD80 mRNA levels were significantly lower in the non-inflammatory dysplastic colonic mucosa of patients with one or more methylated genes and inversely correlated with patients’ methylation scores (τ = −0.41, p = 0.05 and τ = −0.37, p = 0.05, respectively). Treatment with 5-Aza-2′-deoxycytidine significantly increased CD80 expression both in terms of the level of CD80 mRNA (p = 0.007) and of CD80+ cells (p = 0.003). Conclusions These results indicate that the failure of immune surveillance mechanisms in non-inflammatory colon carcinogenesis may be linked to genomic methylation directly or indirectly affecting CD80 expression. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2405-z) contains supplementary material, which is available to authorized users.


Conclusions:
These results indicate that the failure of immune surveillance mechanisms in non-inflammatory colon carcinogenesis may be linked to genomic methylation directly or indirectly affecting CD80 expression.

Background
Immune surveillance of nascent cancer cells is a fundamental process mediated by T-cells, macrophages, and natural killer cells that work to protect host against the unrestrained proliferation of transformed cells [1]. Full T-cell activation requires the engagement of T-cell receptors with specific major histocompatibility complexes at the surface of antigen-presenting cells in the presence of adequate co-stimulatory signals provided by CD80 or CD86 [2]. Oncogenic insults inducing CD80 expression seem then to be able to modulate the anti-tumor immune response [3]. The significant overexpression of CD80 in the colonic mucosa of patients with ulcerative colitis (UC) and dysplasia as opposed to CD80 downregulation in non-inflammatory colon cancer [4][5][6] have led to the hypothesis that the lack of positive costimulatory molecules is one of the main mechanisms by which colorectal cancer (CRC) escapes immune surveillance [7]. The molecular mechanisms underlying immune surveillance remain, nevertheless, largely unknown.
An altered methylation pattern in cancer cell genomes is a well recognized characteristic of tumor cells, and specific aberrant methylation events take place during the early stages of colorectal carcinogenesis leading to profound modifications in gene expression [8]. The aberrant methylation of H-cadherin (CDH13) commencing at an early stage of colorectal tumorigenesis frequently silences, in fact, the expression of this tumor suppressor gene in colorectal adenomas and cancers [9]. Besides germ-line mutations associated with hereditary familial adenomatous polyposis and somatic mutations in sporadic colorectal tumors, hypermethylation also provides an important mechanism underlying impaired APC function [10]. Moreover, the hypermethylation of the CpG island within the DNA-repair protein O-6-methylguanine-DNAmethyltransferase (MGMT) gene [11] and in the MLH1 gene is associated with a reduced gene expression observed in the majority of sporadic primary CRC with microsatellite instability [12]. Finally, RUNX3 hypermethylation decreases TGF-β/BMP signaling in gastrointestinal cancer cells [13].
In addition to oncogenes or oncosuppressors, some immune stimulatory molecules are regulated in cancer cells by DNA methylation in their promoter regions. MHC class I and its antigen presentation machinery have been shown to be regulated by DNA methylation [14][15][16][17]. Adhesion molecules [14][15][16][17][18], such as ICAM-1 and LFA-3, and costimulatory molecules [17,18], such as CD40 and CD86, can be regulated by DNA methylation in cancer cells. Thus, demethylation treatment can dramatically increase the susceptibility of some tumor cells to T-cell destruction [15,[19][20][21]. Our first step in investigating the role of DNA methylation in CRC immune surveillance consisted in examining the expression of CD80; we then went on to analyze its relationship with genomic methylation during the early stages of colon carcinogenesis.

Patients
A prospective cohort study of healthy controls (n = 30) and patients (n = 24) who underwent colonoscopy for screening or post-operative follow-up or colonic resection for colorectal cancer was designed. Biopsy samples of healthy mucosa (n = 30), of normal and diseased mucosa from patients with dysplastic adenoma (n = 14), and from patients with colon adenocarcinoma (n = 10, one patients staged T1N0M0, two T2N0M0, two T3N0M0, four T3N1M0 and one T3N1M1) were collected.
Patients' and controls' characteristics are outlined in Table 1.

Gene expression analysis
Total RNA was extracted using the RNeasy Plus Kit (Qiagen) according to the manufacturer's protocol. At that point 0.5 μg total RNA was converted to cDNA using the Applied Biosystems cDNA Synthesis kit, again, according to the manufacturer's instructions. DNA methyltransferase-1, −3a, −3b (DNMT-) and CD80 mRNA expression was quantified by real time qRT-PCR. Specific mRNA transcripts were quantified with SYBR Green PCR Master Mix in a ABI PRISM 7000 Sequence Detection System (Applied Biosystems). ACTB expression was used as reference gene for normalization. Primer sequences and PCR conditions are outlined in Table 2.

Methylation specific PCR
Genomic DNA was extracted from tissues using a DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer's directions. Sodium bisulfate modification of gDNA was performed using the EZ DNA Methylation-Gold Kit (Zymo Research) following the manufacturer's instructions. The primers for APC, CDH13, MGMT, MLH1 and RUNX3 methylationspecific PCR and PCR conditions are outlined in Table 2. The EpiTect PCR Control DNA Set (Qiagen) was used as the positive control for the methylated and unmethylated genes. Each PCR was done in a final volume of 25 μL containing 10 ng of bisulfite converted gDNA, 1× PCR buffer, 0.25 mmol/L deoxynucleotide triphosphate, 400 nmol/L each primer, and 1 unit ZymoTaq (Zymo Research). PCR amplification was done as follows: 95°C for 10 min followed by 40 cycles at 95°C for 30 s, the specific annealing temperature for each gene for 30 s and 72°C for 30s; and, in a final extension step, at 72°C for 7 min. PCR products were resolved by 3 % agarose gel electrophoresis and each case was scored as

Methylation status of gene promoters involved in the early stages of colon carcinogenesis
The promoter methylation status of five genes known to be associated with early stages of colon carcinogenesis was assessed in the colonic mucosa of 54 subjects (Table 1). They consisted of 30 healthy controls, 14 with adenoma and dysplasia, and 10 with colorectal adenocarcinoma. The promoter regions of APC, CDH13, MGMT1 and RUNX3 were more frequently methylated in patients with invasive adenocarcinoma (p = 0.04, p = 0.02, p = 0.03 and p = 0.05, respectively) (Fig. 1a). Consequently, the methylation score was significantly higher in patients with cancer than those with pre-neoplastic lesions (i.e. adenomas) and healthy subjects (p = 0.04) (Fig. 1b).

CD80 and DNMTs mRNA expression along colonic carcinogenesis pathway
The expression of CD80 and methyltransferase (DNMT)-1, −3a, and −3b was quantified in the different steps of sporadic carcinogenesis. CD80 mRNA expression did not show any significant variation as shown in Fig. 2a. On the other hand, in colonic lesions the expression of all three DNMTs tended to increase progressively along the carcinogenesis pathways, as shown in Fig. 2b-d.

Relationship between the methylation status, DNMTs and CD80 expression in colon carcinogenesis
As shown in Fig. 3, CD80 mRNA levels were inversely correlated with the DNMT3A mRNA levels in healthy colonic mucosa of patients with adenoma and with

DNA methylation affects CD80 expression in intestinal epithelial cells
To assess the impact of DNA methylation on CD80 gene expression levels in intestinal cancer cells, HT29, HTC15 and LoVo cell lines were treated with 5AZAdC, the DNMTs inhibitor. As shown in Fig. 4a and b, at basal levels CD80 mRNA was barely detectable and the percentage of CD80 + HT29, HTC15 and LoVo cells was < 2 %. Adding 5AZAdC to HT29, HTC15 and LoVo cells coltures significantly increased CD80 expression both in terms of CD80 mRNA levels (p = 0.005, p = 0.02 and p = 0.02, respectively) and of CD80 + cells (p = 0.001, p = 0.02 and p = 0.04, respectively).

Discussion
Cancer immune surveillance is a fundamental process by which immune cells protect against cancer formation by identifying and eliminating tumor cells on the basis of their expression of tumor-specific and stressinduced antigens [1]. While it has been suggested that the lack of positive co-stimulatory molecules is the mechanism by which tumor cells evade immune surveillance, the molecular events underlying this process remain elusive. In this study, we show that CD80 mRNA expression, the co-stimulatory molecule found in colon carcinogenesis, inversely correlates with the inducible DNMTs expression in healthy tissue of patients with adenoma or cancer and with the number of genes that have promoters which are often aberrantly hypermethylated at early stages of colorectal tumorigenesis and, as a consequence, thought to contribute to CRC pathogenesis [8]. Indeed, APC, CDH13, MGMT1 and RUNX3 methylation frequency of gene promoters as well as DNMTs expression progressively increases along the pathway towards invasive cancer in sporadic colonic carcinogenesis. Taken together these data suggest that DNA methylation plays a role in CD80 expression. This association has been found to be notable at the dysplastic stage of carcinogenesis when the CD80-driven immune surveillance process might be critical in preventing cancer cells from escaping [6,22]. But although two prospective studies characterized by adequate follow-up and precise definition of the adenoma site failed to show complete regression or spontaneous reduction of polyps [23,24], the findings of a more recent epidemiological investigation suggest that dysplastic adenoma prevalence in humans is caused by a dynamic process including both adenoma formation and regression [25]. Our data are, indeed, the first to suggest that DNA methylation of CD80 gene may explain why immune surveillance mechanisms can at times fail in patients with non-inflammatory colorectal carcinogenesis.
Interestingly, a recent investigation reported hypermethylation of the CD80 promoter in mice tumours, and treatment with decitabine, a DNA methyltransferase inhibitor, was found to enhance CD80 expression in EL4 cells via demethylation of CpG dinucleotide sites in the promoter of CD80 gene resulting in T lymphocyte infiltration into tumors and, ultimately, in tumor rejection [26]. Likewise, epigenetic silencing of CD70, a CD80 related co-stimulatory molecule, by DNA methylation was noted during breast cancer progression in an in vitro model [27].
Our in vitro assay on HT29, HTC15 and LoVo CRC cell lines further supports the hypothesis that DNA methylation is involved in the inhibition of the gene expression of CD80. There was, in fact, a 10-fold increase in CD80 mRNA levels and the number of CD80+ cells was doubled following treatment with a DNA methyltransferase inhibitor. These data are particularly relevant because they confirm the hypothesis of a role of gene methylation in the inhibition of CD80 expression in three different CRC cell lines.
A limit of the present study is the lack of a direct evidence of DNA methylation of the CD80 promoter. Usually, but not exclusively, methylation occurs at the so-called CpG islands and if hypermethylation involves the promoter region it may result in gene silencing. CD80 promoter do not contain any sequence with characteristics making methylation easy to detect (CD80 at chr3:119524293-119559634 Genome Browser http://genome.ucsc.edu/index.html). Given the difficulty in directly assessing whether and at what stage CD80 methylation takes place along the colorectal carcinogenesis pathway and in order to assess if hypermethylation plays a role in CD80 down-regulation in human colorectal tumorigenesis, we examined the correlation between expression of CD80 and the methylation of genes involved in the early stages of CRC carcinogenesis and the expression of DNMTs and attempted to verify our hypothesis by developing an in vitro assay. Finally, this study did not explore the interactions of CD80 and PD-1 with B7H1 (programmed death ligand 1 [PD-L1]) [28]. In fact, although they are both located on antigen presenting cells' surface, CD80 also has an appreciable affinity for the PD-L1 [29]. Their interplay has a pivotal role in controlling T cell activation, proliferation, anergy, and apoptosis and methylation might play a role in their regulation. However, the interactions between the two pathways remain still unknown.